A single-arm phase II trial of UGT1A1 genotype–guided high-dose irinotecan rechallenge in refractory metastatic colorectal cancer
Frontiers in Oncology · 22.07.2026 · 16
DOI: 10.3389/fonc.2026.1907944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 22.07.2026. Verfasst von Hana Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center 323, Goyang, Republic of Korea. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There is an unmet need for optimal third- or later-line treatment options for refractory or metastatic colorectal cancer (mCRC) patients. This phase II study investigated whether high-dose irinotecan rechallenge based on UGT1A1 genotype improves the 12-week disease control rate (12w DCR), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety in refractory mCRC patients.
Methods
Patients who had previously received more than two lines of chemotherapy, including 5-fluorouracil, oxaliplatin, irinotecan and had shown either a partial response or durable response for more than 24 weeks to irinotecan were included. Patients without the defective allele of UGT1A1 ( UGT1A1 *1/*1) and one defective allele ( UGT1A1 *1/*6, *1/*28) were treated with intravenous irinotecan at doses of 300 mg/m 2 and 250 mg/m 2 , respectively, every 2 weeks until disease progression or unacceptable toxicity.
Results
A total of 32 patients was enrolled between October 2020 and March 2023. The primary endpoint, 12w DCR was 40.6% (13 of 32 patients). The ORR was 15.6% (5 of 32). The median OS was 9.3 months (95% CI, 5.3 to 13.3) and the median PFS was 2.9 months (95% CI, 2.5 to 3.3). Grade 3 or higher adverse events were observed in 19 patients (59.4%). Dose reduction due to adverse events occurred in 9 patients (50.0%) in UGT1A1 wild-type group and 4 patients (28.6%) in the heterozygous group.
Conclusion
High-dose irinotecan rechallenge guided by UGT1A1 genotype was feasible and showed meaningful disease control in third-line or later settings for mCRC patients previously responsive to irinotecan.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center 323, Goyang, Republic of Korea.
- Department of Laboratory Medicine, Research Institute and Hospital, National Cancer Center 323, Goyang, Republic of Korea.
Zitieren
APA
Kim, H., Hong, J., Kong, S. Y., & Choi, M. K. (2026). A single-arm phase II trial of UGT1A1 genotype–guided high-dose irinotecan rechallenge in refractory metastatic colorectal cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1907944
Vancouver
Kim H, Hong J, Kong SY, Choi MK. A single-arm phase II trial of UGT1A1 genotype–guided high-dose irinotecan rechallenge in refractory metastatic colorectal cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1907944
BibTeX
@article{Kim2026,
author = {Kim, Hana and Hong, Joohyun and Kong, Sun-Young and Choi, Moon Ki},
title = {A single-arm phase II trial of UGT1A1 genotype–guided high-dose irinotecan rechallenge in refractory metastatic colorectal cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1907944}
}
EUVIMED